Clinical trials: Subjects With Type 2 Diabetes Mellitus.
Type 2 Diabetes Mellitus
Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes
This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus® injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.
- Trial name
- NCT00097500
- Testing
- exenatide, Insulin glargine, Metformin
- Where
- 3 sites in Finland, Netherlands and 1 more
- Volunteers
- 69 people
- Sponsor
- AstraZeneca
Diabetes Mellitus II
Dose Ranging Study With LT, Monotherapy, PPAR
A Randomized, Double-Blind, Dose-Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects with Type 2 Diabetes
- Trial name
- NCT00240383
- Testing
- Muraglitazar
- Where
- 272 sites in United States, Argentina and 14 more
- Volunteers
- 1,260 people
- Sponsor
- Bristol-Myers Squibb
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects
This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02479022
- Testing
- Insulin 320, insulin glargine
- Where
- Germany
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, and the United States of America (USA). The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) plus insulin aspart (IAsp)…
- Trial name
- BEGIN™ (NCT00972283)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 136 sites in United States, Bulgaria and 10 more
- Volunteers
- 1,006 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Type 2 Diabetes Mellitus
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the…
- Trial name
- NCT02148861
- Testing
- Insulin icodec, insulin degludec
- Where
- Germany
- Volunteers
- 49 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted globally (the United States of America excepted). This trial is designed to show the effect of treatment with liraglutide when added to existing glimepiride therapy and to compare this to both glimepiride…
- Trial name
- LEAD-1 (NCT00318422)
- Testing
- liraglutide, rosiglitazone, glimepiride
- Where
- 127 sites in Argentina, Australia and 21 more
- Volunteers
- 1,041 people
- Sponsor
- Novo Nordisk A/S
Exocrine Pancreatic Insufficiency in Subjects With Diabetes Mellitus Type 2
A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2
maldigestion of dietary macronutrients (pancreas not producing enough enzymes for digestion of fat, sugars and proteins) in diabetes type II
- Trial name
- NCT02009410
- Testing
- Creon
- Where
- 10 sites in Germany, Spain
- Sponsor
- Abbott
Type II Diabetes
Safety, Pharmacokinetics, and Food Effect of PS1 in Subjects
This is a phase I, double-blind, placebo-controlled, randomized, single- and multiple-ascending dose study to evaluate new study intervention, PS1.
- Trial name
- NCT05176210
- Testing
- PS1
- Where
- Taiwan
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Pharmasaga Co. Ltd.
Diabetes Mellitus Type 2, Hypovitaminosis D
Diabetes Intervention Trial With Vitamin D in Subjects of Nordic and Sub-Indian Ethnicity
The aim of this 6 months study is to evaluate the metabolic effects of 400.000-600.000 IU of vitamin D supplementation in subjects with type 2 diabetes and hypovitaminosis D.
- Trial name
- DIVINE (NCT00992797)
- Testing
- Cholecalciferol, Orange juice
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- University Hospital, Aker
Diabetes, Diabetes Mellitus, Type 2
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (IDeg) and liraglutide (Lira) in subjects with type 2 diabetes.
- Trial name
- DUAL™ I (NCT01336023)
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- 302 sites in United States, Australia and 18 more
- Volunteers
- 1,663 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects
The purpose of this research study is to look at concentrations of GSK189075, WELLBUTRIN SR and active metabolic products in blood samples when doses of both drugs are taken by mouth. Doses are either taken alone or together.
- Trial name
- NCT00625859
- Testing
- GSK189075, Bupropion
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
T2DM
A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes
This is a randomized, double-blind, placebo-controlled, single-dose escalation trial was designed. There are 6 dose groups and 1 optional dose group: 0.5 mg, 2 mg, 8 mg, 25mg, 50 mg, 100 mg and 150 mg (optional).
- Trial name
- NCT05996380
- Testing
- SHR-3167
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
Dose Response Study in Japanese Patients
This is a 12-week study to determine the effect on glucose and lipids, safety, and tolerability of four doses of tesaglitazar (0.25, 0.5, 0.75 and 1 mg) compared with placebo in patients with type 2 diabetes.
- Trial name
- NCT00261417
- Testing
- Tesaglitazar
- Where
- 20 sites in Japan
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period
This study is conducted in the United States of America (USA). The aim of this study is to assess longitudinal variation of immune biomarkers in subjects with type 1 diabetes (T1D), type 2 diabetes (T2D) and healthy, non-diabetic…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01900834
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate
Insulin resistance (IR) is common in many metabolic disorders and predisposes an individual to Type 2 Diabetes Mellitus (T2DM), the Metabolic Syndrome and coronary atherosclerosis.
- Trial name
- NCT00551564
- Testing
- rosiglitazone maleate
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes, Overweight
Diabetes and Metabolic Postprandial Responses
The aim of this trial was to compare postprandial metabolic response to glucose load in healthy overweight and type 2 diabetic subjects, by using glycemia, insulinemia, lipid profile, nutrient oxidation follow-up.
- Trial name
- NCT00767208
- Testing
- oral glucose load
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche en Nutrition Humaine Rhone-Alpe
Type 2 Diabetes Mellitus
A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).
This is an efficacy and safety study of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy.
- Trial name
- NCT02033889
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Glimepiride
- Volunteers
- 621 people
- Sponsor
- Merck Sharp & Dohme LLC
Epicardial Fat
Semaglutide vs Dulaglutide on Epicardial Adipose Tissue
Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R).
- Trial name
- NCT04200625
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Miami
Type 2 Diabetes Mellitus
Absolute Bioavailability Study With Bexagliflozin
The purpose of this study is to determine the absolute bioavailability of bexagliflozin following a single oral dose co-administered with an intravenous dose.
- Trial name
- NCT03417076
- Testing
- Bexagliflozin
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Theracos
Diabetes Mellitus, Type 2
A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
This study compares 2 medicines for type 2 diabetes: oral semaglutide (a new medicine) and sitagliptin (a medicine doctors can already prescribe).
- Trial name
- PIONEER 12 (NCT04017832)
- Testing
- Oral semaglutide, Sitagliptin
- Where
- 93 sites in Algeria, Brazil and 7 more
- Volunteers
- 1,441 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.